Abstract
In the past few decades, the cholinergic theory of Alzheimer's disease has been promoted as a crucial tool for the creation of new drugs. In this study, a series of novel quinazolinone scaffold were synthesized, docked and predicted for their ADMET studies for cholinesterase inhibitors against Alzheimer’s disease. Docking study were performed, using Autodock 4.2 for the synthesized compounds 4a-c and were observed to be well accommodated in the active site of AChE compared to standard Donepezil. Compounds 4d-f were most suggested novel quinazolinone derivative that the inhibitor exhibited two hydrogen bonding interactions with AChE. In-silico drug-likeness and pharmacokinetic properties was predicted using Swiss ADME, pkCSM software. All synthesized compounds 4a-f having better pharmacokinetic profile for potential to act as a cholinesterase inhibitors against Alzheimer’s disease.
 Keywords: Alzheimer’s disease, Quinazolinone, Pharmacokinetic profile, Cholinesterase, Acetylcholinesterase (AChE).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
